Once-weekly insulin icodec as novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials
Pooled result · HbA1c reductionResult — go to the resultMD −0.11 % 95% CI −0.23 to 0.01Authors' conclusion
This study suggests similar efficacy and safety between insulin icodec and regular basal insulin. Further clinical trials are still needed to confirm the results of our study.
Study context
- Population
- Patients with T2D; trials comparing insulin icodec with basal insulin (Cochrane Library, Scopus, ClinicalTrials.gov, Medline to August 19th, 2023)
- Participants
- 3,963 patients9 trials
- Comparison
- Once-weekly insulin icodec vs regular basal insulin
- Outcome
- Efficacy and safety of insulin icodec vs regular basal insulin for T2D management
Methodological detailsrandom-effects models, Risk of bias (RoB v2): 5 trials low risk, 4 some concern due to protocol deviations
- Random-effects models
- Risk of bias (RoB v2): 5 trials low risk, 4 some concern due to protocol deviations
Pooled result
HbA1c reduction
MD
−0.11 %
95% CI −0.23 to 0.01
P = 0.08
Insulin icodecvs Regular basal insulin
MD −0.11 % (95% CI −0.23 to 0.01); P = 0.08
As reported in the abstract
Further pooled results
Fasting plasma glucose (FPG) and body weight change from baseline
- FPG and body weight change did not differ significantly between groups
Safety
Adverse events
- Total AEs higher with insulin icodec
- Serious AEs and clinically significant hypoglycaemia did not differ significantly
Original publication
Once-weekly insulin icodec as novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. Published 28 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →